Dako and Quintiles have announced a strategic alliance to advance personalised medicine through the co-development of targeted therapies and companion diagnostics.
Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products, and will provide of support to AstraZeneca for the development of a leading oncology compound.
Quintiles Global Central Laboratories senior vice-president Thomas Wollman said that combining core competencies in translational medicine, biomarker discovery and managing clinical trials with Dako's expertise in companion diagnostics would help select the right patients for the right clinical trials.
Under the alliance, Dako will develop cancer diagnostic tests and Quintiles will conduct the tests as part of the clinical validation.
The two companies will continue to work independently with bio-pharmaceutical companies and service providers in the industry.